635 related articles for article (PubMed ID: 12743132)
1. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
2. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Rowinsky EK
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
6. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.
Yong HY; Koh MS; Moon A
Expert Opin Investig Drugs; 2009 Dec; 18(12):1893-905. PubMed ID: 19852565
[TBL] [Abstract][Full Text] [Related]
7. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
9. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.
Rowinsky EK
Drugs; 2000; 60 Suppl 1():1-14; discussion 41-2. PubMed ID: 11129167
[TBL] [Abstract][Full Text] [Related]
10. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
11. Single cell network profiling (SCNP): mapping drug and target interactions.
Covey TM; Putta S; Cesano A
Assay Drug Dev Technol; 2010 Jun; 8(3):321-43. PubMed ID: 20158439
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
14. Issues and progress with protein kinase inhibitors for cancer treatment.
Dancey J; Sausville EA
Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
[TBL] [Abstract][Full Text] [Related]
15. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
16. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
17. Targeting mTOR signaling in lung cancer.
Marinov M; Fischer B; Arcaro A
Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
[TBL] [Abstract][Full Text] [Related]
18. [Signal transduction inhibitor].
Ueda Y; Saijo N
Gan To Kagaku Ryoho; 2001 May; 28(5):591-600. PubMed ID: 11383206
[TBL] [Abstract][Full Text] [Related]
19. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
